Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
- Chun-Jun Li†1,
- Xiao-Juan Liu†1,
- Lian Bai1,
- Qian Yu1,
- Qiu-Mei Zhang1,
- Pei Yu1 and
- De-Min Yu1Email author
© Li et al.; licensee BioMed Central Ltd. 2014
Received: 9 March 2014
Accepted: 26 May 2014
Published: 31 May 2014
The oral DPP-4 inhibitors are new incretin-based therapies for treatment of type 2 diabetes. To assess the efficacy and safety of three DPP-4 inhibitors (Saxagliptin, Sitagliptin and Vildagliptin) as add-on therapy to dual combination of traditional oral hypoglycemic agents in Chinese type 2 diabetes patients.
In this 24-week, randomized, open-label, parallel clinical trial, we enrolled inadequately controlled (glycosylated haemoglobin A1c [HbA1c] ≥7.5% to ≤10%) patients with type 2 diabetes, who were treated by dual combination of metformin and another traditional oral hypoglycemic agent (glimepiride, acarbose or pioglitazone). 207 patients had been randomized to add-on 5 mg saxagliptin group or 100 mg sitagliptin once daily group, or 50 mg vildagliptin twice daily group for 24 weeks. HbA1c, fasting and postprandial blood glucose (FBG and P2hBG), body weight, body mass index (BMI), episodes of hypoglycemia and adverse events were evaluated.
After 24 weeks, HbA1c, FBG, and P2hBG of each group were significantly decreased. (saxagliptin vs vildagliptin vs sitagliptin: HbA1c: -1.2% vs -1.3% vs -1.1%; FBG: -1.8 mmol/l vs -2.4 mmol/l vs -1.5 mmol/l; P2hBG: -3.4 mmol/l vs -3.7 mmol/l vs -3.2 mmol/l). The changes of HbA1c and P2hBG among the three groups had no significance. However, vildagliptin-added group showed the greatest reduction (p < 0.001), while, sitagliptin-added group showed the lowest reduction (p < 0.001) in terms of FPG changes. Proportions of patients achieving HbA1c < 7% at the end were similar in three groups (saxagliptin 59%, vildagliptin 65%, sitagliptin 59%). Mild hypoglycemia was commonly reported among the three groups (saxagliptin 6%, vildagliptin 2%, sitagliptin 3%). No significant between-group difference was shown in other AEs.
The three gliptins showed almost similar glycemic control and incidence of adverse events. However, for FBG control, saxagliptin demonstrated superiority to sitagliptin, while, inferiority to vildagliptin.
Type 2 diabetes mellitus (T2DM) is a complex disease mainly caused by impaired beta cell function and insulin resistance. In China, a total diabetes prevalence of 9.7% (92.4 million adults) was reported by the China National Diabetes and Metabolic Disorders Study in 2007–2008, while the prevalence of pre-diabetes was estimated to be 15.5% (148 million adults) . Moreover, the prevalence of T2DM in Asia is expected to increase over the next 20 years due to a sedentary lifestyle combined with the increase in obesity and overweight resulting from economic development, and the changes in diet . The increasing prevalence of type 2 diabetes and inadequate control of blood glucose in patients correlates with higher risk for cataracts, retinopathy, neuropathy, and other diabetic microvascular complications [3, 4]. There is also a strong correlation between mean glycated hemoglobin (HbA1c) levels over time and the development and progression of diabetic complications. Both the American Diabetes Association and the Chinese Diabetes Society advocate a HbA1c goal of <7.0% for individuals with T2DM [5, 6], although adequate glycemic control is difficult to achieve in China [1, 7]. Therefore, early and long-term control of type 2 diabetes is required.
According to Chinese guidelines for T2DM treatment, metformin is recommended when diet and lifestyle interventions alone are unable to maintain blood glucose control at target levels [8, 9]. Failure of monotherapy over time suggests the need for combination therapy to achieve or maintain glycemic goals . Several oral therapies are approved for use in combination with metformin; however, they are not always effective and are associated with side effects . Sulfonylureas are associated with hypoglycemia and weight gain; thiazolidinediones are associated with weight gain, fluid retention, congestive heart failure, and fractures; and α- glucosidase inhibitors are associated with abdominal discomfort, increased intestinal gas, and diarrhea . Given these considerations, there remains a substantial unmet need for an agent that could improve β-cell function, improve glycaemic control, and have less adverse effects.
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral anti-diabetic agents that increase circulating concentrations of the glucagon-like peptide-1 (GLP-1) . GLP-1 released after meals but degraded by dipeptidyl peptidase-4 (DPP-4) rapidly. The DPP-4 inhibitors block the rapid inactivation of GLP-1 and improve glycaemic control . It has been indicated that dipeptidyl peptidase-4 inhibitors (DPP4i) are superior to traditional oral hypoglycemic agents in terms of the efficacy and tolerability [14–17]. Such priority can be also seen from the rising status in the authoritative guideline for preventing and treating diabetes. In the 2009 position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) for the management of hyperglycemia in type 2 diabetes, DPP4i were considered as less well-validated therapies and not recommended in the main therapy steps . However, the 2012 statement of the ADA and EASD included DPP4i as second-option medication when metformin fails, despite there was no specific preference compared with other oral agents (sulfonylurea and thiazolidinedione) in the same position .
Several DPP-4 inhibitors have been produced, including vildagliptin, sitagliptin, and saxagliptin .
For monotherapy in Asian countries, all of the three agents are demonstrated to be effective and safe comparing with placebo [21–23]. When it comes to combination therapy, the three agents demonstrated great glycemic control and tolerance in Asian patients with T2DM who had inadequate glycemic control with metformin or glimepiride [24–28]. So far, no trial has been conducted head-to-head comparing the three DPP-4 inhibitors in Asian. The current clinical trial was designed as a prospective study to investigate the efficacy and safety of vildagliptin, saxagliptin, or sitagliptin added to the existing therapy in Chinese type 2 diabetes patients, who had inadequate glycemic control with conventional oral hypoglycemic agents.
This was a 24-week, randomized, open-label, parallel clinic study in patients with T2DM who had inadequate glycaemic control with dual combination of metformin and other traditional oral hypoglycemic agents (glimepiride, acarbose and pioglitazone). Patients were screened for the eligibility at Visit 1 (week -12) and were randomized (1 : 1: 1) at Visit 2 (week 0, baseline) to receive saxagliptin 5 mg qd, vildagliptin 50 mg bid, or sitagliptin 100 mg qd for 24 weeks. The randomization was stratified on the basis of the patient’s background treatment into metformin with glimepiride, or acarbose, or pioglitazone combination therapy. During the 24-week treatment period, patients were required to visit the outpatient once every two weeks, and telephone contact every week. The dosage of the background oral hypoglycemic agents was adjusted through the whole treatment period if the hypoglycemia occurred, based on the value of blood glucose and physicians’ experience.
Patients were recruited from the Metabolic Disease Hospital of Tianjin Medical University between Jan 2012 and Jan 2013. All subjects provided written informed consent and confirmed their willingness to perform glucose self-monitoring. This study design was approved by the local ethics committee review board and was conducted using Good Clinical Practice in accordance with the Declaration of Helsinki.
Patients with T2DM (aged 18–70) who were inadequately controlled by dual combination of traditional oral hypoglycemic agents with HbA1c of 7.5–10.0% and body mass index (BMI) of 22.5–30 kg/m2 were eligible for enrollment. Patients were required to have been treated with metformin and another oral hypoglycemic agent (glimepiride, acarbose, or pioglitazone) for at least 12 weeks and be on a stable recommended dose.
Patients were excluded if they had a history of type 1 diabetes mellitus or diabetes due to pancreatic injury or secondary forms of diabetes, any acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state (coma) within past 6 months, myocardial infarction, unstable angina or coronary artery bypass surgery within past 6 months. Patients with congestive heart failure, liver disease such as cirrhosis or chronic active hepatitis or with any of the following laboratory abnormalities at Visit 1 were also excluded: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 times the upper limit of normal (ULN), total bilirubin > 2 times ULN, serum creatinine levels [men: ≥ 1.5 mg/dl (132 μmol/l); women: ≥ 1.4 mg/dl (123 μmol/l)] or thyroid-stimulating hormone beyond the normal range, fasting triglycerides > 500 mg/dl (5.6 mmol/l).
Assessments included HbA1c, FBG and P2hBG at baseline and the endpoint of 24 weeks.
Adverse events (AEs) were recorded and assessed for their severity and the potential relationship to the study drug. Patients were educated how to recognize the signs and symptoms of hypoglycemia and asked to test glucose whenever they experienced such events and to record the results if possible. Hypoglycaemia was defined as the presence of symptoms suggestive of hypoglycaemia, confirmed by self-monitored blood glucose < 56 mg/dl (3.1 mmol/l). Severe hypoglycaemia was defined as an episode requiring assistance of another party. All assessments were performed in a central laboratory with standardized and validated procedures according to Good Laboratory Practice.
Results are described as mean ± standard deviation or n and%. 2-tailed paired t-test was used for comparison of pre- and post-treatment values within group. One-way univariate analysis of variance (ANOVA) and polynomial was used to compare the differences in clinical characteristics among the three groups at baseline and after treatment assessed for significance using for the discrete or continuous data. For analysis of differences in the frequency distributions, the chi-square test and Fisher’s exact test were used. Statistical analyses were performed using SPSS windows version 19.0. P value < 0.05 was considered to be statistically significant.
Demographic and baseline characteristics
Total n = 190
Saxagliptin n = 66
Vildagliptin n = 63
Sitagliptin n = 61
Age (years), mean ± SD
46.6 ± 9.0
46.5 ± 10.7
44.8 ± 8.5
48.6 ± 11.3
23 ~ 72
23 ~ 72
25 ~ 63
29 ~ 70
Age (years), n (%)
50 ~ 65 years
Gender, n (%)
Duration of diabetes (years), n (%)
1 ~ 5 years
Body weight (kg), mean ± SD
74.4 ± 11.1
77.2 ± 15.1
72.7 ± 11.3
73.2 ± 10.9
BMI (kg/m2), mean ± SD
26.3 ± 2.8
26.9 ± 3.1
25.3 ± 2.8
26.6 ± 3.3
HbA1c (%), mean ± SD
8.72 ± 1.01
8.86 ± 1.13
8.75 ± 1.15
8.54 ± 1.19
FBG (mmol/l), mean ± SD
8.46 ± 1.61
8.36 ± 2.04
8.79 ± 1.80
8.22 ± 1.77
P2hBG(mmol/l), mean ± SD
11.58 ± 2.49
11.77 ± 3.07
11.98 ± 2.46
10.98 ± 2.93
Therapy, n (%)
Metformin with glimepiride
Metformin with acarbose
Metformin with pioglitazone
Changes of variables related with HbA 1c , FBG, and P2hBG after 24-week treatment
Baseline (mean ± s.d)
24 weeks (mean ± s.d)
Mean changes from baseline (95% CI)
★Difference in mean change (95% CI)
ΔDifference in mean change (95% CI)
8.75 ± 1.15
7.41 ± 1.43
-1.34 (-2.03, -0.64)**
8.86 ± 1.13
7.65 ± 1.41
-1.21 (-1.91, -0.51)**
0.13 (-0.66, 0.40)
8.54 ± 1.19
7.47 ± 1.42
-1.07 (-1.64, -0.50)**
0.27 (-0.80, 0.26)
0.14 (-0.67, 0.39)
8.79 ± 1.80
6.35 ± 1.57
-2.44 (-3.01, -1.87)**
8.36 ± 2.04
6.53 ± 1.92
-1.83 (-2.13, -1.53)**
0.61 (0.30, 0.92)##
8.22 ± 1.77
6.73 ± 1.69
-1.49 (-1.69, -1.29)**
0.95 (0.64, 1.26)##
0.34 (0.03, 0.65)Δ
11.98 ± 2.46
8.27 ± 2.28
-3.71 (-4.16, -3.26)**
11.77 ± 3.07
8.36 ± 2.70
-3.41 (-4.33, -2.49)**
0.30 (-0.32, 0.92)
10.98 ± 2.93
7.82 ± 2.58
-3.16 (-4.03, -2.29)**
0.55 (-0.07, 1.17)
-0.25 (-0.37, 0.87)
The patients achieving target HbA1c of less than 6.5% were 32% (21 patients) of saxagliptin-added group, 36% (23 patients) of vildagliptin-added group, and 25% (15 patients) of sitagliptin-added group, without significant differences among the three groups (p = 0.14). Those with HbA1c less than 7.0% were 59% (39 patients) of saxagliptin-added group, 65% (41 patients) of vildagliptin-added group, and 59% (36 patients) of sitagliptin-added group, with no significant differences among the three groups (p = 0.51).
Saxagliptin n = 68
Vildagliptin n = 63
Sitagliptin n = 63
Elevated liver enzymes
Chest discomfort & dyspnea
Other adverse events, including diarrhea, headache, edema, abdominal discomfort, elevated liver enzymes, nasosinusitis and chest discomfort or dyspnea were similarly happened among the three study populations. During 24-week study, one patient in saxagliptin-added group withdrawn from the study, who was discontinued for peripheral edema with unknown reasons.
The current study evaluated the efficacy and safety of adding saxagliptin, vildaglitpin or sitagliptin as add-on therapy to dual combination of metformin and other oral hypoglycemic agents (glimepiride, acarbose and pioglitazone) of patients with inadequately glycemic control. Adding treatment with saxagliptin, vildagliptin, and sitagliptin all resulted in significant improvements in glycemic control. There was no significant difference among the three treatment groups of HbA1c changes and P2hBG changes, as well as the proportion of achieving target HbA1c levels. Nevertheless, it was demonstrated that saxagliptin was superior to sitagliptin, while, inferior to vildagliptin in terms of changes in FBG after 24-week treatment. The incidence of adverse events with three DPP-4 inhibitors was similar, and all of them were well tolerated.
This study showed no significant reductions in HbA1c from baseline to week 24 among the three DPP-4 inhibitors-added groups, decreasing by 1.1 ~ 1.3%. Besides, about 60% of the study participants reached a target HbA1c of less than 7.0%, but the rest of the study participants remained in poorly glycemic control. And only about 30% of the subjects reached a target HbA1c less than 6.5%. While, previous placebo-controlled trials showed that the DPP-4 inhibitors could decrease HbA1c by about 0.6 ~ 0.9% [29–31]. When added to metformin, sulphonylureas or alpha-glucosidase inhibitors, DPP-4 inhibitors could reduce HbA1c by about 0.6 ~ 1.1% . Moreover, adding DPP-4 inhibitors to ongoing metformin allowed approximately 30–50% patients to achieve HbA1c levels < 7.0% [33–36]. The differences between our results and previous studies might be influenced by different racial background of study populations, baseline HbA1c levels, BMI, types and dosages of background drugs and prescribed doses of the study drugs. Most of Previous reports were performed in western countries, a majority of participants are Caucasian, whose baseline HbA1c levels were 8.1-10%, and BMIs were 26 ~ 30 kg/m2 [33–38]. Whereas the patients of our study are Orientals, who had HbA1c levels of 7.5-10%, and BMIs of 22.5-30 kg/m2. Such difference might be attributed to the subjects in our study having relatively mild hyperglycemia and lower BMIs, as well as, maybe Orientals are more sensitive to DPP-4 inhibitors. Several clinical trials also showed similar HbA1c reductions (1.1 - 1.4%) with our results in Asian countries [27, 39].
As indicated in our study, vildagliptin showed the greatest reductions of FBG, while, sitagliptin showed the smallest reductions. This might be explained by the structure of the three DPP-4 inhibitors. Saxagliptin and vildagliptin are cyanopyrrolidines that form a covalent bond with the active site serine , which may result in more robust inhibition to DPP-4 and greater potency of lowering blood glucose level than sitagliptin with nonvalent bond with DPP-4. And it is might be relational that the usage of vildagliptin was twice daily, while, saxagliptin and sitagliptin was once daily. A previous study showed that vildagliptin induced better circadian glycaemic control than sitagliptin with a significant decrease on overall hyperglycemia, mainly driven by reduction on basal hyperglycaemia . Several Asian clinical trials demonstrated that vildagliptin 50 mg twice daily was associated with significantly greater HbA1c reduction than sitagliptin 100 mg once daily in patients of mean HbA1c ranged from 7.4% to 7.8% [42–44].
The reported numbers of hypoglycaemic events in studies with vildagliptin and sitagliptin are very low. A pooled analysis for sitagliptin in monotherapy showed that the incidence of hypoglycaemia was 1.2% after treatment with sitagliptin at 100 mg daily versus 0.9% in the placebo group . Also as add-on therapy to metformin, DPP-4 inhibitiors showed a low degree of hypoglycaemia. Thus, when compared to sulphonylurea as add-on to metformin, sitagliptin showed substantially lower risk of hypoglycaemia (5%) than glipizide (32%) . When combined with sulphonylurea, DPP-4 inhibitions showed increased risk of hypoglycaemia. Thus, when sitagliptin was added to ongoing glimepiride, there was an increased incidence of hypoglycaemia (12% vs. 2% in the group given glimepiride alone) . Furthermore, when vildagliptin was added to glimepiride, a slight increase in the incidence of hypoglycaemia was reported (1.2% vs. 0.6% during treatment with glimepiride alone) . Overall, these studies show a low risk of hypoglycaemia during treatment with DPP-4 inhibition.
In many previous studies, the overall prevalence of adverse events was similar to that seen in placebo groups both in monotherapy and in combination therapy with metformin, sulphonylurea or alpha-glucosidase inhibitors. Nevertheless, in some studies, adverse events such as upper respiratory tract infection, nasopharyngitis and headache were reported, although the association of these adverse events with the compounds has not been established. So far, vildagliptin and sitagliptin have now been examined in a large number of subjects and shown to be tolerable and safe, both in short-term studies and in studies up to 1 year of duration [27, 37–39, 46]. Similarly, saxagliptin is also tolerable and safe [29, 47], although experience with this compound is more limited. The main adverse event with metformin was diarrhea, with glimepiride was hypoglycemia and weight gain, with pioglitazone was edema due to fluid retention and weight gain. However, the symptoms were transient in the majority of the study participants and the causal relationship between the study drugs and symptoms is uncertain.
Limitation and conclusion
There were still several limitations in our study. Firstly, 24 weeks is too short a study duration to evaluate long-term glycemic control, weight loss, and β-cell preservation. Secondly, patients were enrolled based on specific criteria and were followed according to the study schedule, which may not reflect the real clinical use. Thirdly, as the patients were evaluated at outpatient, no specific compliance data were collected. Moreover, our study is small and had an open-label design, which are both limiting factors for the generalization of the data, the limitation should be considered.
The current study demonstrated that the efficacy and tolerability of saxagliptin, vildagliptin, and sitagliptin are similar, with no significant differences, when used to treat type 2 diabetic patients with inadequate blood glucose control by dual combination of metformin and another traditional oral hypoglycemic agent (glimepiride, acarbose, or pioglitazone). But vildagliptin showed grater FBG reduction than sitagliptin. This trial is the first randomized controlled trial to evaluate the efficacy of commonly-used antidiabetic agents in Chinese type 2 diabetic patients. Specific characteristics of the study drugs should be considered when choosing an appropriate agent. To use these results as valuable information for selecting an oral hypoglycemic agent, more detailed subgroup analyses and further investigation would be recommended.
This work was supported by the National Nature Science Foundation of China No. 81300663 (to C.J.L.), and grants from Tianjin Health Bureau Technology Fund No. 2013KZ098 (to C.J.L.). The authors would like to thank all the subjects and investigators for their participation in this study.
- Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J, China National Diabetes and Metabolic Disorders Study Group: Prevalence of diabetes among men and women in China. N Engl J Med. 2010, 12: 1090-1101.View ArticleGoogle Scholar
- Turner RC, Cull CA, Frighi V, Holman RR, UK Prospective Diabetes Study (UKPDS) Group: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999, 281: 2005-2012. 10.1001/jama.281.21.2005.View ArticlePubMedGoogle Scholar
- Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature. 2001, 414: 782-787. 10.1038/414782a.View ArticlePubMedGoogle Scholar
- Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004, 27: 1047-1053. 10.2337/diacare.27.5.1047.View ArticlePubMedGoogle Scholar
- Chinese Diabetes Society: China guideline for type 2 diabetes. Chin J Diabetes Mellitus. 2010, 13 (suppl 2): 6-56.Google Scholar
- American Diabetes Association: Standards of medical care in diabetes–2013. Diabetes Care. 2013, 13 (suppl 1): S11-S66.View ArticleGoogle Scholar
- Zhao D, Zhao F, Li Y, Zheng Z: Projected and observed diabetes epidemics in China and beyond. Curr Cardiol Rep. 2012, 13: 106-111.View ArticleGoogle Scholar
- Asian-Pacific Type 2 Diabetes Policy Group: Type 2 diabetes: practical targets and treatments. Melbourne/Singapore: International Diabetes Institute (IDI)/In Vivo Communications (Asia) Pte Limited, http://www.idf.org/webdata/docs/T2D_practical_tt.pdf; 2005 [accessed 7.07.10], 4
- International Diabetes Federation: Clinical guidelines task force, global guideline for type 2 diabetes. Brussels, Belgium: International Diabetes Federation, http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf; 2005 [accessed 7.07.10]
- DeFronzo RA: From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009, 58 (4): 773-795. 10.2337/db09-9028.PubMed CentralView ArticlePubMedGoogle Scholar
- Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009, 15 (6): 540-559. 10.4158/EP.15.6.540.View ArticlePubMedGoogle Scholar
- Inzucchi SE, McGuire DK: New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation. 2008, 117: 574-584. 10.1161/CIRCULATIONAHA.107.735795.View ArticlePubMedGoogle Scholar
- Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R: Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with up titration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009, 63: 1395-1406. 10.1111/j.1742-1241.2009.02143.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Ji LN, Pan CY, Lu JM, Li H, Li Q, Li QF, Peng YD, Tian HM, Yao C, Zhao ZG, Zhang RY, Wang XL, Wang L, VISION Study Group: Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study. Cardiovasc Diabetol. 2013, 12: 118-10.1186/1475-2840-12-118.PubMed CentralView ArticlePubMedGoogle Scholar
- Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S: Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009, 11 (2): 157-166. 10.1111/j.1463-1326.2008.00994.x.View ArticlePubMedGoogle Scholar
- Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, Nishii M, Arjona Ferreira JC, Amatruda JM: Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab. 2010, 12: 613-622. 10.1111/j.1463-1326.2010.01197.x.View ArticlePubMedGoogle Scholar
- Takihata M, Nakamura A, Tajima K, Inazumi T, Komatsu Y, Tamura H, Yamazaki S, Kondo Y, Yamada M, Kimura M, Terauchi Y: Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial. Diabetes Obes Metab. 2013, 15 (5): 455-462. 10.1111/dom.12055.View ArticlePubMedGoogle Scholar
- Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA, Cersosimo E: Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008, 294: E846-E852. 10.1152/ajpendo.00030.2008.View ArticlePubMedGoogle Scholar
- Cersosimo E, Gastaldelli A, Cervera A, Wajcberg E, Sriwijilkamol A, Fernandez M, Zuo P, Petz R, Triplitt C, Musi N, DeFronzo RA: Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. J Clin Endocrinol Metab. 2011, 96: 1763-1770. 10.1210/jc.2010-2146.View ArticlePubMedGoogle Scholar
- Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP: Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type2 diabetes: a review of recent clinical trials. Curr Med Res Opin. 2008, 24: 489-496. 10.1185/030079908X261069.View ArticlePubMedGoogle Scholar
- Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J: Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diatetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev. 2012, 28 (3): 268-275. 10.1002/dmrr.1306.View ArticlePubMedGoogle Scholar
- Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ, Stein PP: Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008, 79: 291-298. 10.1016/j.diabres.2007.08.021.View ArticlePubMedGoogle Scholar
- Kikuchia M, Abe N, Kato M, Terao S, Mimori N, Tachibana H: Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009, 83: 233-240. 10.1016/j.diabres.2008.10.006.View ArticleGoogle Scholar
- Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, Lv X, Lu J, Bader G, Institution Investigators: Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012, 14 (8): 737-744. 10.1111/j.1463-1326.2012.01593.x.View ArticlePubMedGoogle Scholar
- Kikuchi M, Haneda M, Koya D, Tobe K, Onishi Y, Couturier A, Mimori N, Inaba Y, Goodman M: Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2010, 89: 216-223. 10.1016/j.diabres.2010.04.017.View ArticlePubMedGoogle Scholar
- Yang W, Chang Yu P, Tou C, Zhao J, Gause-Nilsson I: Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract. 2011, 94: 217-224. 10.1016/j.diabres.2011.07.035.View ArticlePubMedGoogle Scholar
- Soo Chung H, Kyu Lee M: Efficacy of Sitagliptin when added to ongoing therapy in Korean subjects with type 2 diabetes mellitus. Diabetes Metab J. 2011, 35: 411-417. 10.4093/dmj.2011.35.4.411.View ArticleGoogle Scholar
- Takahara M, Shiraiwa T, Kaneto H, Katakami N, Matsuoka TA, Shimomura I: Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy. Endocr J. 2012, 59 (12): 1131-1136. 10.1507/endocrj.EJ12-0220.View ArticlePubMedGoogle Scholar
- Rosenstock J, Aguilar-Salinas CA, Klein E: Once-daily saxagliptin monotherapy improves glycemic control in drug-naive patients with type 2 diabetes. Diabetes. 2008, 57 (suppl 1): A154-Google Scholar
- Dejager S, Razac S, Foley JE, Schweizer A: Vildagliptin in drug-naive patients with type 2 diabetes: a 24 week double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007, 39: 218-223. 10.1055/s-2007-970422.View ArticlePubMedGoogle Scholar
- Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, Sitagliptin Study 021 Group: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006, 29: 2632-2637. 10.2337/dc06-0703.View ArticlePubMedGoogle Scholar
- Ahre’n B: Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab. 2009, 23: 487-498. 10.1016/j.beem.2009.03.003.View ArticleGoogle Scholar
- DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS, Saxagliptin 014 Study Group: The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care. 2009, 32: 1649-1655. 10.2337/dc08-1984.PubMed CentralView ArticlePubMedGoogle Scholar
- Charbonnel B, Karasik A, Liu J, Wu M, Meininger G: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006, 29: 2638-2643. 10.2337/dc06-0706.View ArticlePubMedGoogle Scholar
- Scott R, Loeys T, Davies MJ, Engel SS: Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008, 10: 959-969. 10.1111/j.1463-1326.2007.00839.x.View ArticlePubMedGoogle Scholar
- Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M: Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008, 24: 537-550. 10.1185/030079908X260925.View ArticlePubMedGoogle Scholar
- Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, Couturier A, Baron MA: Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008, 10: 1047-1056. 10.1111/j.1463-1326.2008.00859.x.View ArticlePubMedGoogle Scholar
- Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007, 9: 733-745. 10.1111/j.1463-1326.2007.00744.x.View ArticlePubMedGoogle Scholar
- Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, Wang Y, Foley JE: Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med. 2008, 25: 435-441. 10.1111/j.1464-5491.2008.02391.x.View ArticlePubMedGoogle Scholar
- Schweizer A, Couturier A, Foley JE, Dejager S: Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabet Med. 2007, 24 (9): 955-961. 10.1111/j.1464-5491.2007.02191.x.View ArticlePubMedGoogle Scholar
- Guerci B, Monnier L, Serusclat P, Petit C, Valensi P, Huet D, Raccah D, Colette C, Quéré S, Dejager S: Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab. 2012, 38 (4): 359-366. 10.1016/j.diabet.2012.06.001.View ArticlePubMedGoogle Scholar
- Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB: Comparative efficacy of Vildagliptin and Sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Clin Drug Investig. 2011, 31 (9): 665-674. 10.2165/11592490-000000000-00000.View ArticlePubMedGoogle Scholar
- Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K, Arjona Ferreira JC, Amatruda J: Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J. 2010, 57 (5): 383-394. 10.1507/endocrj.K09E-272.View ArticlePubMedGoogle Scholar
- Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H: Vildagliptin dosedependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009, 83 (2): 233-240. 10.1016/j.diabres.2008.10.006.View ArticlePubMedGoogle Scholar
- Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP, Sitagliptin Study 024 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007, 9: 194-205. 10.1111/j.1463-1326.2006.00704.x.View ArticlePubMedGoogle Scholar
- Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, Sitagliptin 036 Study Group: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007, 30: 1979-1987. 10.2337/dc07-0627.View ArticlePubMedGoogle Scholar
- Rosenstock J, Sankoh S, List JF: Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008, 10: 376-386. 10.1111/j.1463-1326.2008.00876.x.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.